December 20, 2022 | Press Release Landmark Study by Boston Cell Standards Validates First Reference Standards for Immunohistochemistry Testing News > Press Release > Landmark Study by Boston Cell Standards Validates First Reference Standards for Immunohistochemistry Testing
April 27, 2026 Boston Cell Standards Enters Final Phase of FDA MDDT Program to Qualify First-in-Industry Platform to Standardize Cancer Diagnostic Assays Continue Reading
January 20, 2026 Boston Cell Standards Calibrator technology presented at The Pathological Society of Great Britain & Ireland Winter Meeting 2026 Continue Reading
January 6, 2026 International study demonstrates the effectiveness of Boston Cell Standards Calibrators for measuring analytical sensitivity used for breast cancer diagnosis. Continue Reading